ABSTRACT: Positron emission tomography provides a method for the quantitation of regional function within the living human brain. Studies of cerebral metabolism and blood flow in patients with Huntington's disease, Parkinson's disease and focal dystonia have revealed functional abnormalities within substructures of the basal ganglia. Recent developments permit assessment of both pre-synaptic and post-synaptic function in dopaminergic pathways. These techniques are now being applied to studies of movement disorders in human subjects. RESUME: La tomographic par emission de positrons dans les desordres du mouvements La tomographie par Amission de positrons (PET scan) est une m6thode de quantification des fonctions regionales dans le cerveau humain vivant. L'erude du mdtabolisme c6r6bral et du flot sanguin chez des patients souffrant de chorde de Huntington, de maladie de Parkinson et de dystonie focale montre des anomalies fonctionnelles a l'inte>ieur meme des sous-structures des noyaux gris centraux. Des ddveloppements regents permettent d'6tudier les fonctions prd et post-synaptiques dans les voies dopaminergiques. Ces techniques sont maintenant utilisdes pour l'6tude des ddsordres du mouvement chez l'humain.
Positron emission tomography (PET) is a method which is used to measure the concentration of positron-emitting radiopharmaceuticals in the human brain in vivo. The use of this technique in conjunction with appropriate labelled compounds and tracer kinetic models enables the quantitation of regionally selective biochemical and physiological processes in health and disease.
This review is divided into two parts. The first section deals with the methodology which is in routine use at a number of PET centres for the measurement of cerebral metabolism and blood flow, and clinical studies which have been performed using these methods in patients with movement disorders. The second section deals with PET techniques which have been developed more recently to study functions in dopaminergic pathways in man.
CEREBRAL METABOLISM AND BLOOD FLOW
The major energy expenditure in the brain is utilised by ion transport mechanisms for pumping sodium and potassium across neuronal membranes to maintain the electrochemical gradients necessary for the generation of action potentials (Mata et al., 1980) . Aerobic glucose metabolism is responsible for the bulk of the necessary energy production. Therefore, the mapping of regional cerebral glucose metabolism (CMRG) or oxygen metabolism (CMR0 2 ) provides a functional image of brain activity.
The approach which has been used with PET for CMRG measurement is based on the l4 C-2-deoxyglucose (DG) autoradiographic method developed by Sokoloff and co-workers (1977) for use in animals. This method depends on the following unique properties of DG. The bidirectional transport of DG across the blood brain barrier and its initial hexokinase-catalyzed phosphorylation is similar to that of glucose. Unlike glucose, however, the product of this reaction (DG-6-phosphate) cannot be metabolized further and is essentially trapped within the tissue. Dephosphorylation by g4ucose-6-phosphatase does occur, but only very slowly. The accumulation of DG-6-P in the tissue is therefore directly related to the rate of DG phosphorylation by hexokinase. An operational equation has been derived (Sokoloff et al., 1977) which expresses glucose consumption per unit mass of tissue in terms of measurable variables. This method has been used extensively with tissue autoradiography in animals for the measurement of regional CMRG in both physiological and pathological studies (for review see Sokoloff, 1981) .
As originally designed, this method required direct measurement of the regional radioactivity concentration in the brain after DG administration and therefore could not be applied to LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES man. The development of PET, however, made it possible to make these measurements noninvasively. Reivich et al. (1979) demonstrated the use of this model for CMRG measurements in man with PET and the tracer l8 F-fluoro-2-deoxyglucose (FDG) which behaves in a similar fashion to DG. The Sokoloff model was subsequently extended to include the dephosphorylation reaction which was found to be significant for the later times employed with PET measurements Huang et al., 1980) .This model is now utilized for in vivo measurements of CMRG in man in numerous. PET centres throughout the world.
Cerebral oxygen extraction may be measured using inhaled l5 0-labelled oxygen. Two major approaches have been developed for this measurement. A steady-state approach with continuous tracer inhalation has been widely used (Jones et al., 1976; Subramanyam et al., 1978; Frackowiak et al., 1980) . More recently, an approach which combines the data obtained from PET measurements of cerebral blood flow and blood volume with that from a single breath inhalation of O l5 0 has been described and validated . With either of these techniques, cerebral oxygen utilization is calculated from the extraction, the measured regional cerebral blood flow, and the arterial oxygen content.
CLINICAL STUDIES OF MOVEMENT DISORDERS

Hereditary chorea
Huntington's disease (HD) is a lethal inherited degenerative disorder characterized by the onset of chorea and personality disturbances in mid-adulthood. Pathologically there is evidence of widespread neuronal loss affecting mainly the caudate and putamen (Bruyn, 1973) . This is accompanied by striatal atrophy which may be demonstrated by x-ray computed tomography (CT). In early HD, however, no CT changes may be evident.
Clear evidence for an abnormality of striatal glucose metabolism in HD has been obtained using PET. Kuhl et al. (1982) made PET measurements of CMRG in 13 patients with HD and compared these data with that from 40 normal subjects. The results showed a characteristic decrease in striatal glucose metabolism. Although most of their patients had CT evidence of ventricular dilatation and caudate atrophy, it was postulated that the local hypometabolism appears early, preceding bulk tissue loss. These workers also found caudate hypometabolism in 6 of 15 at-risk subjects (ages 12 to 53 years) studied. They have therefore suggested that striatal glucose utilization may be reduced in carriers of the HD gene before the onset of symptoms of HD, but long term follow up of these will be necessary to confirm this hypothesis. Martin et al. (1984c) have studied a group of patients with early HD who had either minimal or no evidence of caudate atrophy on CT. In comparisons of CMRG with normal subjects statistically significant hypometabolism in both caudate and putamen was demonstrated. Neither these workers nor Kuhl et al. (1982) found any significant metabolic changes in whole brain, cerebral cortex, or thalamus.
In contrast to HD, benign hereditary chorea (BHC) is a non-progressive inherited disorder characterized by the presence of chorea without associated dementia. The pathophysiological substrate of BHC remains unknown. PET studies in patients with this disorder have shown a spectrum of changes in striatal metabolism (Suchowersky et al., 1984) . Patients with the most severe choreiform movements had caudate hypometabolism in the same range as those with HD. Mildly affected patients showed a slight decrease in caudate metabolism which was not statistically significant, but did demonstrate a much higher degree of caudate asymmetry than seen in normals.
These PET measurements of CMRG in HD and in BHC clearly demonstrate the functional involvement of the striatum in the production of choreiform movements. They do not, however, reveal which neurotransmitter systems are involved.
Parkinson's disease
The critical pathological process in Parkinson's disease (PD) is selective degeneration of nigrostriatal dopaminergic neurons leading to striatal dopamine depletion (Hornykiewicz, 1972) . Although dopamine is known to be an inhibitory neurotransmitter, it is not well understood how the discrete lesion of PD affects basal ganglia functioning. Cerebral glucose utilization has been studied by several groups in animals with selective unilateral nigrostriatal lesions (Ferron et al., 1979; Kozlowski and Marshall, 1980; Wooten and Collins, 1981; Schwartz et al., 1976; Sagar and Snodgrass, 1980) . The most consistent abnormality noted has been a unilateral increase in metabolism in the globus pallidus ipsilateral to a nigrostriatal lesion.
Preliminary studies of CMRG measured with PET and the FDG technique in patients with predominantly unilateral PD have been reported (Martin et al., 1984a) . No consistent cortical or thalamic asymmetry was noted, but a striking degree of asymmetry was evident in the inferior region of the basal ganglia, in some patients. The affected basal ganglia (i.e., contralateral to the affected limbs) showed increased CMRG with the degree of increase corresponding approximately to the severity of disease. In the most severely affected patient a 54% increase was noted in metabolic rate on the affected side vs. the unaffected side, whereas in the least affected patient no asymmetry was noted.
Measurements of CMR0 2 and CBF in unilateral PD have been reported (Leendersetal., 1983; Raichleetal., 1984) . Both of these groups demonstrated asymmetric basal ganglia metabolism with increased CMR0 2 evident in the basal ganglia contralateral to the affected limbs. By using a stereotactic method for anatomical localization, Raichle et al. (1984) were able to demonstrate that the globus pallidus was the sub-structure primarily responsible for the observed metabolic change.
Patients with bilateral PD have been studied. Leenders et al. (1983) found regional CBF and CMR0 2 in cortical areas and basal ganglia to be similar to measurements in normal volunteers. Basal ganglia CMR0 2 was lower in the bilateral PD patients than in the unilateral patients, possibly because of more prolonged duration of disease in the former group. By using the FDG method, Rougemont et al. (1983) measured CMRG in four bilateral PD patients but found no consistent difference when compared to normal control subjects. Kuhl et al. (1984) observed a moderate reduction (average 18% decrease) in global CMRG but no significant changes in striatal metabolism.
The acute effect of L-dopa on blood flow and metabolism has also been studied by the Hammersmith group (Leenders et al., 1983; Wolfsonetal., 1984) . In patients studied one hour after a single oral dose of L-dopa a 10-80% increase in CBF was seen (Leenders et al., 1983) . The increase in cortical areas was found to correlate with the plasma L-dopa level, but not in the basal ganglia. Increased post-Sinemet CBF has also been found by Volume 12, No. 1 -February 1985 THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES Raichle et al. (1984) . The effect of L-dopa on CMR0 2 is less clear. Leenders et al. (1983) report a decrease in CMRO2 in all brain areas following acute L-dopa administration whereas Raichle et al. (1984) report an increase. In patients on maintenance L-dopa treatment, Leenders et al. (1983) report a significant increase in basal ganglia CMR0 2 as compared to the drug free state. Methodological differences relating to the necessity for maintaining a constant physiological state during sequential l5 02 and H 2 ' 5 0/C l5 02 scans may well explain the apparent disagreement in CMR0 2 changes.
These studies do permit several conclusions to be made concerning cerebral metabolism and blood flow in PD. Asymmetrical basal ganglia metabolism does occur in patients with predominantly unilateral PD, with changes which are similar to those seen in experimental animals with unilateral substantia nigra lesions (Wooten and Collins, 1981) . Second, the administration of L-dopa produces a generalized increase in CBF. This may be secondary to increased metabolism induced by L-dopa, to a direct effect on the blood vessel wall, or to some combination of these two mechanisms. As suggested by Leenders et al. (1983) , the first mechanism may be significant primarily in basal ganglia whereas the second mechanism may be significant throughout the brain. It is clearly important to control for the effects of medication in future studies of cerebral blood flow and metabolism in man.
Dystonia
The study of patients with dystonic movements affecting the head or the trunk presents a major difficulty. During the emission scan the head must be held immobile for a period ranging from 40 seconds to 60 min. or more depending on the scanning technique used. This can prove impossible for these patients even with the short scanning times used with the CBF methodology of Raichle et al. (1983) . One potential solution for the problem would be the use of a rigid head holding device such as that of Mazziotta et al. (1982) or that of Greitz et al. (1980) . With our FDG studies, we have chosen instead to use pharmacological restraint with intravenous diazepam. Although a sedating medication may be expected to alter CBF and metabolism, its use with the FDG model should be acceptable provided it is not given until most of the tracer has been phosphorylated. We administer intravenous diazepam in a dose sufficient to permit comfortable head positioning and gentle restraint with a moulded thermoplastic face mask similar to that used by Ter-Pogossian et al. (1982) , starting at about 30 min. after the administration of FDG. The resulting CMRG measurement reflects primarily the cerebral metabolism integrated over the 30 min. prior to diazepam administration and is affected little by the diazepam itself.
We have studied CMRG in a series of patients (n= 13) with spasmodic torticollis using this method of head positioning (Martin etal., 1984b) . In these patients basal ganglia CMRG did not differ from control values, but the degree of putaminal asymmetry (9-20%) did significantly exceed that seen in normals (5 ± 5%). The direction of asymmetry was not related to the direction of head turning. Although this work is still in progress, the preliminary analysis does suggest the presence of metabolic abnormalities within the basal ganglia with the major abnormality within the putamen. This is consistent with the hypothesis that the putamen is the major site of pathophysiologic involvement in dystonia (Burton etal., 1984; Narbona etal., 1984) . The data suggest that in torticollis there may be a functional imbalance between the two sides rather than a unilateral abnormality in basal ganglia function.
Basal ganglia abnormalities have also been demonstrated in paroxysmal hemidystonia by Perlmutter and Raichle (1984) . Their patient had normal brain anatomy on CT scan, but decreased oxygen metabolism in the basal ganglia contralateral to the affected limbs. The data showed a large area of abnormality in the basal ganglia region making it impossible to determine which substructure was responsible forthe patient's symptoms.
DOPAMINERGIC PATHWAYS
Pre-synaptic function
It has recently become feasible with PET to visualize the distribution of dopamine in vivo. This has been made possible by the development of l8 F-6-fluoro-L-dopa (FD) which behaves as an analog of L-dopa (Garnett et al., 1983a) . Decarboxylation of FD is thought to occur in the terminals of the nigro-striatal neurons resulting in the formation of 6-fluorodopamine which is stored in pre-synaptic vesicles. The accumulation of activity within the striatum following FD administration has been well demonstrated in both baboon (Garnett et al., 1983b) and man (Garnett etal., 1983a) .
Abnormal FD uptake in patients with hemiparkinsonism has been reported (Garnett et al., 1984) . The accumulation of radioactivity was found to be reduced in the basal ganglia contralateral to the affected limbs. This reduction was evident primarily in the putamen; caudate activity was also reduced, but to a lesser extent. We have demonstrated similar changes in FD studies of PD patients with asymmetric clinical involvement. As pointed out by Garnett and co-workers, it is not yet known whether the reduced l8 F accumulation is due to loss of dopaminergic neurons or whether it represents a functional abnormality of these cells at a relatively early stage of the disease.
The interpretation of FD studies is largely qualitative at present and does not provide quantitative data regarding the kinetics of dopa metabolism. Radioactive imaging techniques, whether tissue autoradiography in animals or "in vivo autoradiography" with PET in man, are able to determine the quantitative distribution of the radioactive label only. The identity of the compound(s) to which the label is attached cannot be determined directly from these studies alone. When l8 F-labelled fluorodopa is administered, several labelled metabolites will be present in brain. These include the 0-methylated compound formed by catechol 0-methyl transferase, as well as fluorinated homovanillic acid and dihydroxyphenylacetic acid. Ultimately, one would like to use tracer kinetic modelling techniques to make quantitative measurements of meaningful biochemical parameters. Some progress to this end has been made by the McMaster group (Garnett et al., 1980) , the Hammersmith group (Leenders et al., personal communication) , and ourselves (unpublished).
Post-synaptic function
The development of radio-labelled ligands which are thought to bind to receptor sites has been useful in studies for measuring receptors both in vitro and in vivo (reviewed by Snyder, 1984) .
The butyrophenone drug spiperone has been used in animal studies of dopamine receptors. Initial results using 3-N-"Cmethylspiperone (NMSP) for imaging dopamine receptors in man have been reported (Wagner et al., 1983) . These studies demonstrated that NMSP was localized in the basal ganglia where it is known that there is a high density of dopamine receptors. This uptake is blocked by the administration of other unlabelled dopamine receptor antagonists in excess, suggesting that NMSP does indeed bind specifically to dopamine receptors.
Studies with NMSP in a series of thirty normal subjects have now been presented (Wong etal., 1984) . Serial studies performed for 2 hours after injections demonstrated progressively increasing caudate and putamen activity and simultaneously a progressive decrease in cerebellar activity. The ratio of caudate to cerebellar activity was found to decrease significantly with age in males, but not in females. This binding was felt to represent an age and sex related decrease in dopamine receptor density.
The use of tracer kinetic modelling techniques in conjunction with such radio-labelled ligands should permit quantitative analysis of drug-binding sites in the brain in vivo. A suitable model has been developed by Mintun and co-workers (1984) . The model makes use of repeated measurements of local radioactivity with PET following tracer administration to characterize the dynamic interplay between the ligand and its receptor. This data is combined with PET measurements of other local physiological variables such as blood volume and blood flow to determine the binding potential of the tissue which is equivalent to the product of the number of binding sites and the binding affinity. These workers have demonstrated the utility of this model with l8 F-spiperone to measure binding potential and spiperone permeability in baboons. The same techniques may be readily applied to similar studies in man.
CONCLUSIONS
Studies of cerebral metabolism and blood flow with PET in movement disorders have demonstrated focal abnormalities secondary to altered neuronal function in the basal ganglia. Objective measurements of parameters concerned with in vivo regional cerebral function in man were previously unavailable. Newer techniques have now emerged for the study of both pre-synaptic and post-synaptic function in dopaminergic pathways. These methods, currently in their infancy, are just starting to be applied to patient studies. It should be possible to employ similar techniques to investigate other neurotransmitter systems once suitably labelled tracer compounds are available. The feasibility of imaging opiate receptors and muscarinic acetylcholine receptors (Eckelman et al., 1984) has been demonstrated in man. This technology will provide a vast potential for the study of pathophysiology of numerous neurological disorders in human subjects.
